Does Gabapentin Reduce Quadriceps Muscle Weakness After Anterior Cruciate Ligament Reconstruction?

Last updated: April 5, 2018
Sponsor: Hospital Authority, Hong Kong
Overall Status: Trial Status Unknown

Phase

2/3

Condition

Sarcopenia

Polymyositis (Inflammatory Muscle Disease)

Treatment

N/A

Clinical Study ID

NCT03496389
Gabapentin ACLR
  • Ages 18-50
  • All Genders

Study Summary

Anterior cruciate ligament (ACL) injury is a common sport injury in both professional and recreational athletes. Furthermore, persistent quadriceps weakness and wasting are frequently observed after anterior cruciate ligament reconstruction (ACLR). Several studies have demonstrated that muscular rehabilitation to normal strength is difficult, protracted, and often not achieved due to the inability to fully activate the quadriceps voluntarily. Pain and disuse are often blamed for the inhibition of muscle activation following joint injury. However, arthrogenic muscle inhibition (AMI) is often overlooked and not addressed. Thus, the magnitude of strength restoration of the quadriceps is frequently restricted despite solid rehabilitation protocols. As AMI is a reflex inhibition of musculature involving the neurotransmitter γ-aminobutyrate (GABA), Gabapentin may have a potential role in modulating AMI, therefore limiting muscle weakness after ACLR.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age 18-50

  2. Unilateral isolated ACL tear for primary ACLR confirmed clinically and radiologically

  3. No concomitant ligamentous, meniscal or chondral injuries.

Exclusion

Exclusion Criteria:

  1. Concomitant multiple ligament injuries including posterior cruciate ligament, medialcollateral ligament ligament, or lateral collateral ligament

  2. Concomitant meniscal injuries

  3. Concomitant chondral injuries

  4. preoperative radiographic signs of arthritis

  5. Revision ACL surgery

  6. Contralateral knee with

  7. Medical co-morbidities including Diabetes Mellitus, chronic renal failure

  8. Documented hypersensitivity to Gabapentin

  9. History of epilepsy

  10. History of depression

  11. Non-compliance to rehabilitation protocol.

Study Design

Total Participants: 30
Study Start date:
July 01, 2018
Estimated Completion Date:
August 01, 2019